Shenzhen Kexing Pharma

Kexing Biopharmaceutical is a prominent Chinese biopharmaceutical enterprise specializing in the research, development, production, and sale of recombinant protein therapeutics and microecological preparations. The company's core commercial portfolio includes established brands such as EPOSINO (erythropoietin), WHITE-C (filgrastim), and SINOGEN (interferon α1b), which address critical needs in nephrology, oncology, and infectious diseases. Beyond its internal R&D, Kexing has aggressively pursued a "globalization" strategy, licensing in high-value biosimilars like infliximab and adalimumab for international commercialization. The company maintains high-standard GMP manufacturing facilities and an extensive marketing network covering both domestic Chinese and emerging overseas markets. Kexing is currently expanding its pipeline into innovative biologics and complex small molecules to drive long-term growth.